



CEREBRAL BLOOD FLOW IN RATS AFTER TREATMENT WITH THE PRIMARY  
SENSORY NEUROTOXIN CAPSAICIN

Stephen Helps, B.Sc.

Thesis submitted for the degree of Master of Science,

Department of Physiology,

School of Medicine,

The University of Adelaide.

21st December 1987

ABBREVIATIONS USED

CBF	cerebral blood flow
CCK-8	cholecystokinin
CGRP	calcitonin gene related peptide
CMR-glucose	cerebral metabolic rate for glucose
CMR-O <sub>2</sub>	cerebral metabolic rate for oxygen
CVR	cerebrovascular resistance
DMSO	dimethyl sulfoxide
HCO <sub>3</sub> <sup>-</sup>	bicarbonate ion
ICP	intracranial pressure
IU/ml	international units/ml (concentration)
MABP	mean arterial blood pressure
μg	micrograms (mass)
μl	microlitres (volume)
ml	millilitres (volume)
mM	milli Molar (concentration)
mmHg	millimetres mercury (pressure)
N <sub>2</sub> O	nitrous oxide
ngm	nanograms (mass)
NPY	neuropeptide Y
PaCO <sub>2</sub>	arterial carbon dioxide partial pressure
PaO <sub>2</sub>	arterial oxygen partial pressure
t <sub>1/2</sub>	half life
T°C	temperature in degress celcius
TWEEN	polyoxyethelene-sorbitan mono-oleate (TWEEN-80)
VIP	vasoactive intestinal polypeptide

LIST OF CONTENTS

LIST OF FIGURES	v
LIST OF TABLES	vii
SUMMARY	ix
DECLARATION	xii
ACKNOWLEDGEMENTS	xiii
CHAPTER 1	1
1.1 PROPERTIES OF THE CEREBRAL CIRCULATION	1
1.1.1 Carbon dioxide response	2
1.1.2 Arterial pH response	4
1.1.3 Oxygen response	4
1.1.4 Arterial pressure response	5
1.1.5 Venous pressure response	7
1.2 CEREBRAL BLOOD FLOW REGULATION	7
1.2.1 Myogenic hypothesis	7
1.2.2 Humoral hypothesis	9
1.2.3 Intracerebral neurogenic mechanisms	9
1.2.3.1 Serotonin	10
1.2.3.2 Noradrenaline	11
1.2.4 Extracerebral neurogenic mechanisms	12
1.2.4.1 Classical neurogenic mechanism	12
1.2.4.2 Neoclassical neurogenic mechanism	13
1.2.5 Neuronal regulation?	14
1.3 NEUROPEPTIDE INNERVATION	15
1.4 SUBSTANCE P	15
1.4.1 Substance P in primary sensory neurons	16
1.4.2 Substance P in the cerebral vasculature	16
1.4.3 Vasodilatation by substance P	17
1.5 SOMATOSTATIN	19
1.5.1 Mode of action of somatostatin	19
1.5.2 Haemodynamic effects of somatostatin	20
1.5.3 Somatostatin in sensory structures	21
1.6 NEUROPEPTIDE DEPLETION	22
1.6.1 Capsaicin	22
1.6.2 Cysteamine	25
CHAPTER 2	31
2.1 MATERIALS AND METHODS	31
2.1.1 The clearance technique for measuring blood flow	31
2.1.1.1 Compartmental analysis	33
2.1.1.2 Initial slope index analysis	34
2.1.1.3 Stochastic analysis	34
2.1.2 Hydrogen clearance	35
2.1.3 Experimental method	38
2.1.3.1 Animals	38
2.1.3.2 Surgical procedures	39
2.1.3.3 Systemic Capsaicin treatment	42
2.1.3.4 Systemic cysteamine treatment	43
2.1.3.5 Trigeminal Capsaicin treatment	43
2.1.4 Biochemistry	47
2.1.4.1 Tissue preparation	47
2.1.4.2 Radioimmunoassay	48
2.1.4.2.1 Radioimmunoassay Tracer	49
2.1.4.2.2 Radioimmunoassay method	50
2.1.4.3 Lowry protein determination	51
2.2 DATA REDUCTION	52

CHAPTER 3	54
3.1 CBF AFTER SYSTEMIC CAPSAICIN OR CYSTEAMINE	54
3.2 AIMS	55
3.3 HYPOTHESIS TO BE TESTED	55
3.4 EXPERIMENTAL METHOD	56
3.5 RESULTS	56
3.5.1 CBF changes after capsaicin treatment	57
3.5.2 Peptide levels after capsaicin treatment	57
3.5.3 CBF changes after cysteamine treatment	58
3.5.4 Peptide levels after cysteamine treatment	58
3.6 DISCUSSION	66
CHAPTER 4	68
4.1 CBF AFTER TRIGEMINAL CAPSAICIN	68
4.2 AIMS	69
4.3 HYPOTHESIS	69
4.4 EXPERIMENTAL METHOD	70
4.5 RESULTS	71
4.5.1 CBF changes DMSO/saline group	71
4.5.2 CBF changes TWEEN/saline group	72
4.5.3 Peptide levels	74
4.6 DISCUSSION	80
CHAPTER 5	95
5.1 GENERAL DISCUSSION	95
5.1.1 CBF after systemic capsaicin or cysteamine	97
5.1.2 CBF after trigeminal capsaicin	100
5.2 CONCLUSION	103
APPENDIX A	104
A.1 CMR-glucose and CBF using autoradiographic techniques	104
A.2 Measurement of CMR-glucose	105
A.3 Measurement of CBF	110
A.4 Summary	114
APPENDIX B	115
B.1 Immunohistochemistry for albumin after capsaicin treatment	115
APPENDIX C	123
C.1 HP-29C Calculator program for calculating CBF	123
C.2 Computer software for statistical analysis	125
C.2.1 MRECTG	127
C.2.2 MSCATG	134
APPENDIX D	138
D.1 Buffer for microvessel isolation	138
D.2 Buffer for perfuse-fixation	138
D.3 Buffer for radioimmunoassay procedures	139
D.4 Buffer for immunohistochemistry	139
APPENDIX E	140
E.1 Abstracts	140
E.2 Meetings attended	140

APPENDIX F	141
F.1 Systemic vehicle treatment raw data	141
F.2 Systemic capsaicin treatment raw data	143
F.3 Systemic cysteamine treatment raw data	144
F.4 Trigeminal DMSO/saline vehicle raw data	145
F.5 Trigeminal DMSO/saline capsaicin raw data	147
F.6 Trigeminal TWEEN/saline vehicle raw data	148
F.7 Trigeminal TWEEN/saline capsaicin raw data	149
 BIBLIOGRAPHY	 152

LIST OF FIGURES

Figure 1.1	Showing the relationship between the pial arteries and the brain parenchyma.	27
Figure 1.2	Showing the variation of CBF with PaCO <sub>2</sub> , with PaO <sub>2</sub> and MABP.	28
Figure 1.3	Showing the distribution of substance P containing nerve fibres.	29
Figure 2.1	Hydrogen clearance curve.	37
Figure 2.2	The experimental environment.	45
Figure 2.3	Trigeminal ganglion injection.	46
Figure 2.4	Radioimmunoassay standard curve.	53
Figure 3.1	CBF at 25, 40 and 55 mmHg PaCO <sub>2</sub> as calculated by linear regression for the capsaicin treated group.	59
Figure 3.2	Levels of substance P and somatostatin in the capsaicin treated group.	62
Figure 3.3	CBF at 25, 40 and 55 mmHg PaCO <sub>2</sub> as calculated by linear regression for the cysteamine treated group.	63
Figure 3.4	Levels of substance P and somatostatin in the cysteamine treated group.	65
Figure 4.1	CBF data for the vehicle only (DMSO/saline) and capsaicin treated groups showing right CBF and left CBF.	75
Figure 4.2	CBF data for the vehicle only (DMSO/saline) and capsaicin treated groups showing right CBF superimposed on right CBF and left superimposed on left CBF.	76
Figure 4.3	CBF data for the vehicle only (TWEEN/saline) and capsaicin treated groups showing right CBF and left CBF.	77

Figure 4.4	CBF data for the vehicle only (TWEEN/saline) and capsaicin treated groups showing right CBF superimposed on right CBF and left superimposed on left CBF.	78
Figure 4.5	Substance P levels in each group for right and left trigeminal ganglia, DMSO/saline and TWEEN/saline groups.	79
Figure A.1	Representative autoradiographs for the CMR-glucose experiments.	109
Figure A.2	Representative autoradiographs for the CBF experiments.	113
Figure B.1	Vehicle treated rat's brain sectioned through the mammillary bodies and stained for immunoreactive rat albumin	119
Figure B.2	Capsaicin treated rat's brain sectioned through the mammillary bodies and stained for immunoreactive rat albumin	120
Figure B.3	Showing a close up view of an arterial segment through the Circle of Willis of a vehicle treated rat.	121
Figure B.4	Showing a close up view of an arterial segment through the Circle of Willis of a capsaicin treated rat.	122

LIST OF TABLES

Table 1.1	Perivascular neurotransmitters in cerebral vessels.	30
Table 3.1	Blood flow values for vehicle and capsaicin treated rats based on a single calculated value for each rat.	59
Table 3.2	Comparison of vehicle and capsaicin treated rats showing pooled data from all experiments.	60
Table 3.3	Neuropeptide data for vehicle and capsaicin treated rats.	61
Table 3.4	Neuropeptide data for vehicle and cysteamine treated rats.	61
Table 3.5	Comparison of vehicle and cysteamine treated rats based on a single calculated value for each rat.	63
Table 3.6	Comparison of vehicle and cysteamine treated rats showing pooled data from all experiments.	64
Table 4.1	Left and right CBF before and at 15, 45, 75 and 105 minutes after injection of TWEEN/saline vehicle.	82
Table 4.2	MABP, PaCO <sub>2</sub> and PaO <sub>2</sub> before and at 15, 45, 75 and 105 minutes after injection of TWEEN/saline vehicle.	83
Table 4.3	Heart rate (HRate), temperature (T°C), HCO <sub>3</sub> <sup>-</sup> and pH before and at 15, 45, 75 and 105 minutes after injection of TWEEN/saline vehicle.	84
Table 4.4	Left and right CBF before and at 15, 45, 75 and 105 minutes after injection of DMSO/saline vehicle.	85
Table 4.5	MABP, PaCO <sub>2</sub> and PaO <sub>2</sub> before and at 15, 45, 75 and 105 minutes after injection of DMSO/saline vehicle.	86
Table 4.6	Heart rate (HRate), temperature (T°C), HCO <sub>3</sub> <sup>-</sup> and pH before and at 15, 45, 75 and 105 minutes after injection of DMSO/saline vehicle.	87
Table 4.7	Left and right CBF before and at 15, 45, 75 and 105 minutes after injection of TWEEN/saline capsaicin.	88

Table 4.8	MABP, PaCO <sub>2</sub> and PaO <sub>2</sub> before and at 15, 45, 75 and 105 minutes after injection of TWEEN/saline capsaicin.	89
Table 4.9	Heart rate (HRate), temperature (T°C), HCO <sub>3</sub> <sup>-</sup> and pH before and at 15, 45, 75 and 105 minutes after injection of TWEEN/saline capsaicin.	90
Table 4.10	Left and right CBF before and at 15, 45, 75 and 105 minutes after injection of DMSO/saline capsaicin.	91
Table 4.11	MABP, PaCO <sub>2</sub> and PaO <sub>2</sub> before and at 15, 45, 75 and 105 minutes after injection of DMSO/saline capsaicin.	92
Table 4.12	Heart rate (HRate), temperature (T°C), HCO <sub>3</sub> <sup>-</sup> and pH before and at 15, 45, 75 and 105 minutes after injection of DMSO/saline capsaicin.	93
Table 4.13	Substance P levels (pg/μg protein) in trigeminal ganglia in the DMSO/saline group.	94
Table 4.14	Substance P levels (pg/μg protein) in trigeminal ganglia in the TWEEN/saline group.	94
Table A.1	CMR-glucose in μmol/100 gm/minute from rats treated with vehicle only or capsaicin.	108
Table A.2	CBF in mls/min/100gm from rats treated with vehicle only or capsaicin.	112

SUMMARY

Cerebral blood flow (CBF) is tightly coupled to the metabolic demands of the cerebral tissue. Understanding of the mechanisms by which CBF is regulated is incomplete. Several neuronal systems innervate cerebral arteries and veins. These include primary sensory peptidergic, cholinergic and sympathetic systems. The primary sensory innervation contains a number of peptides including substance P. Axons containing substance P are found close to the adventitia of the larger cerebral arteries as well as the pial arteries in several mammalian species. The larger cerebral vessels of the frontal cortex are supplied from the ipsilateral trigeminal ganglion. Neuropeptides contained in this primary sensory innervation are depleted by the neurotoxin capsaicin or by trigeminal ganglionectomy. The presence of other vasodilator fibres has made study of this system difficult.

This study sought to determine whether the peptidergic innervation of the cerebral vasculature plays any functional role in the responsiveness of the vasculature to physiological stimuli. Capsaicin is a neurotoxin with a specific target neuron and a well documented effect on the peptide levels of primary sensory unmyelinated nerves. CBF can be measured repeatedly using the hydrogen clearance technique which employs small platinum electrodes. The electrodes cause little damage to brain.

In the first series of experiments, rats were pre-treated with either capsaicin (an agent which depletes peptide from primary sensory neurons) or with cysteamine (an agent which depletes

somatostatin). The responsiveness of the cerebral vasculature was assessed by measuring (CBF) by the method of hydrogen clearance at hyper- normo- and hypo-carbia. Other parameters such as blood pressure, pH and PaO<sub>2</sub> which affect the CBF were kept constant. The efficacy of peptide depletion was assessed by radioimmunoassay of brain microvessel sonicates and whole brain homogenates. By depleting substance P, a vasodilator in many vascular beds, including the brain, it was expected that the response of the cerebral vasculature to circulating PaCO<sub>2</sub> would be attenuated. However, resting CBF was increased and the responsiveness of the vasculature to PaCO<sub>2</sub> was enhanced after capsaicin treatment. These effects do not appear to be related to changes in cerebral metabolic rate nor was there any vascular degeneration. Substance P levels in the cerebral microvessels were not altered by capsaicin treatment although the levels of substance P in whole brain were reduced. Since somatostatin is a release inhibitor, depletion was expected to increase sensitivity to PaCO<sub>2</sub>. Pretreatment with cysteamine increased CBF at hypocarbia, but not at normocarbia or hypercarbia. Cysteamine reduced somatostatin concentration in whole brain but had no effect on cerebral vessels.

In the second series of experiments, rats were treated with a single dose of capsaicin injected into the right trigeminal ganglion. Changes in steady state CBF were measured by hydrogen clearance. Parameters such as PaCO<sub>2</sub>, mean arterial blood pressure (MABP), pH and PaO<sub>2</sub> were kept constant. The peptide depletion profile was assessed by radioimmunoassay of left and right trigeminal ganglia. Acute treatment with capsaicin was expected to stimulate substance P release from neuron terminals

of the ganglion, provide a vasodilator stimulus and so increase CBF. However, a vehicle containing dimethyl sulfoxide/saline (DMSO) by itself caused a marked reduction in steady state CBF. Capsaicin administered in this vehicle reversed the vasoconstriction, CBF levels remaining normal throughout the experimental period. If capsaicin was administered in a vehicle containing TWEEN/saline no changes in CBF were found. TWEEN/saline by itself caused no changes in CBF.

The experiments reported here provide evidence for the involvement of primary sensory mechanisms in the regulation of CBF. The data demonstrate that the trigeminal ganglion sensory projection to the cerebral vessels has a functional role in the regulation of CBF. Other capsaicin sensitive neuropeptides could be studied and interspecies differences should also be investigated. It would be possible to repeat this series in awake animals and obviate the difficulties interpreting data from an anaesthetised model.

DECLARATION

I certify that this thesis does not incorporate, without acknowledgement, any material previously submitted for a degree or diploma in any University and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Stephen Helps, 1988.

ACKNOWLEDGEMENTS

This project has crossed several areas which do not normally encounter one another. The initial proposals and hypotheses were put forward after lengthy discussions with a number of people and a number of people have sustained me during the execution of the experiments.

My principal supervisor, Dr. Peter Reilly has been tolerant, understanding and always ready to provide support. His candid advice and experience with the practicalities of CBF research and administration have been indispensable to this project. Dr. Gary Scroop has played a less visible but no less essential role, often providing insights not bound by contemporary thinking of how the cerebral vasculature is presumed to be regulated.

My friend Dr. John Oliver (Endocrine Unit, Flinders Medical Centre) provided radioimmunoassay facilities, somatostatin antisera, radioactive tracer, help with data interpretation and considerable inspiration. I doubt the final thesis would have ever been completed without his steady encouragement. The discourse with Dr. Micheal Cain (Endocrine Unit) is also appreciated.

For 5 weeks in June 1985 I was able to work with Dr. J. McCulloch (Wellcome Surgical Institute, Glasgow). This period was particularly busy for everyone and I am especially thankful of the time Dr. McCulloch was able to make available. His enthusiasm and collaboration with what looks like a small part of the work has really extended to and underpinned the whole study.

There are a number of people, including Kathy Cash, Alma Bennett and Anne Schloithe, whose help in the laboratory and experimental theatres is appreciated. Katrina Flynn provided moral support and help with the immunohistochemistry while Dr. Peter Blumbergs assisted in the interpretation of the histological work. The substance P antiserum was donated by Dr. Roger Murphy of Flinders Medical Centre, South Australia.

During this period I was supported by the E.R. Dawes, A.R. Currin, L.C. Hughs Research Fellowship, the Royal Adelaide Hospital Special Purposes Fund and the Neurosurgical Research Foundation.

And my family. They have endured my 2 trips away from home as well as endless weekends and evenings expended on a project which appears to them (and sometimes to me) to never end. To them must the final thanks go.